Early concurrent chemoradiotherapy with prolonged oral etoposide and cisplatin for limited-stage small-cell lung cancer

Japanese Journal of Clinical Oncology

Volumn 33, Issue 12, 2003, Pages 620-625

  Lee, Se Hoon ^a   Ahn, Yong Chan ^a   Kim, Ho Joong ^a   Lim, Do Hoon ^a   Lee, Soon Il ^a   Nam, Eunmi ^a   Park, Se Hoon ^a   Park, Jinny ^a   Lee, Kyung Eun ^a   Park, Joon Oh ^a   Kim, Kihyun ^a   Kim, Won Seog ^a   Jung, Chul Won ^a   Im, Young Hyuck ^a   Kang, Won Ki ^a   Lee, Mark H ^a   Park, Keunchil ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Chemoradiotherapy; Cisplatin; Early concurrent; Etoposide; Small cell lung carcinoma

Indexed keywords

BILIRUBIN; CISPLATIN; CREATININE; ETOPOSIDE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; ESOPHAGITIS; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; LIVER TOXICITY; LUNG SMALL CELL CANCER; LUNG TOXICITY; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; RADIATION DOSE; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; DRUG ADMINISTRATION; FEMALE; LUNG TUMOR; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; ORAL DRUG ADMINISTRATION; SMALL CELL CARCINOMA;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CISPLATIN; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 18544394060     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyg115     Document Type: Article

References (24)

1. Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327:1618-24.
2. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992;10:890-5.
3. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727-33.
4. Tannock IF. Treatment of cancer with radiation and drugs. J Clin Oncol 1996;14:3156-74.
5. Perry MC, Eaton WL, Propert KJ, Ware JH, Zimmer B, Chahinian AP, et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 1987;316:912-8.
6. Work E, Nielsen OS, Bentzen SM, Fode K, Palshof T. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group. J Clin Oncol 1997;15:3030-7.
7. Murray N, Coy P, Pater JL, Hodson I, Arnold A, Zee BC, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1993;11:336-44.
8. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: A randomized study. J Clin Oncol 1997; 15:893-900.
9. Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama. A, Yokota S, et al. Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002;20:3054-60.
10. Sandler AB. Current management of small cell lung cancer. Semin Oncol 1997;24:463-76.
11. Turrisi AT, Sherman CA. The treatment of limited small cell lung cancer: a report of the progress made and future prospects. Eur J Cancer 2002;38: 279-91.
12. Slevin ML, Clark PI, Joel SP, Malik S, Osborne RJ, Gregory WM, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 1989;7:1333-40.
13. Clark PI, Slevin ML, Joel SP, Osborne RJ, Talbot DI, Johnson PW, et al. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 1994;12:1427-35.
14. Murphy PB, Hainsworth JD, Greco FA, Hande KR, DeVore RF, Johnson DH. A phase II trial of cisplatin and prolonged administration of oral etoposide in extensive-stage small cell lung cancer. Cancer 1992;69:370-5.
15. Wolff AC, Ettinger DS, Neuberg D, Comis RL, Ruckdeschel JC, Bonomi PD, et al. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: An Eastern Cooperative Oncology Group pilot study. J Clin Oncol 1995;13:1615-22.
16. Miller AA, Herndon JE II, Hollis DR, Ellerton J, Langleben A, Richards F II, et al. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: A randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1995;13:1871-9.
17. Samantas E, Skarlos DV, Pectasides D, Nicolaides P, Kalofonos H, Mylonakis N, et al. Combination chemotherapy with low doses of weekly carboplatin and oral etoposide in poor risk small cell lung cancer. Lung Cancer 1999;23:159-68.
18. Grunberg SM, Crowley J, Hande KR, Giroux D, Munshi N, Lau DH, et al. Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic, study. Cancer Chemother Pharmacol 1999;44:461-8.
19. Girling DJ. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: A stopped multicentre, randomised trial. Medical Research Council Lung Cancer Working Party. Lancet 1996;348:563-6.
20. Thomas CR Jr, Giroux DJ, Stelzer KJ, Craig JB, Laufman LR, Taylor SA, et al. Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: A phase II study of the Southwest Oncology Group (SWOG-9229). Int J Radiat Oncol Biol Phys 1998;40:1039-47.
21. Lee JS, Scott C, Komaki R, Fossella FV, Dundas GS, McDonald S, et al. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: Radiation therapy oncology group protocol 91-06. J Clin Oncol 1996;14:1055-64.
22. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
23. Turrisi AT III, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265-71.
24. Sohn HJ, Kim S-W, Alm JH, Kang HJ, Park S, Jung HN, et al. Concurrent etoposide/cisplatin combination chemotherapy (EP) and thoracic radiotherapy after two cycles of EP for limited stage small cell lung cancer. Cancer Res Treat 2002;34:409-15 (in Korean).